Floatz logo

Rapamycin

Medulloblastoma

Emory UniversityPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

42 Active assets in the Medulloblastoma cohort.

Asset / SponsorPhaseRating
Olaparib
Fundación de investigación HM
Phase 2BB
Irinotecan
Pfizer
Phase 2BB
Nivolumab
Bristol-Myers Squibb
Phase 2B
Indoximod
Theodore S. Johnson
Phase 2B
Cyclophosphamide
Theodore S. Johnson
Phase 2B

View all 50 →

Same molecule, other indications

Rapamycin is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →